Biotechnology The US Food and Drug Administration Advisory Committee has voted against accelerated approval for eteplirsen, a drug designed to combat Duchenne muscular dystrophy (DMD). The drug was put up for accelerated approval under the FDA Safety and Innovation Act (FDASIA), but the committee found insufficient grounds for approval, noted Dr Nicola Davies in her monthly exclusive FDA Blog for The Pharma Letter. 31 May 2016